A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus
This study tests if an investigational medicine called survodutide helps adults with overweight or obesity and type 2 diabetes lose weight. It aims to see how well the medicine works compared to an inactive placeholder.
You might be able to join if you are 18 or older, have a body mass index of 27 or higher, and have type 2 diabetes. Participants should also have struggled with weight loss through diet changes alone.
You will take either the study medicine or a placebo by giving yourself a weekly injection under the skin for about one and a half years. Everyone in the study also receives helpful counseling on healthy diet and exercise, along with regular check-ins with the study team.
This study has locations in the United States, including Alabama, Arizona, and California. The study status is currently completed.
- 1Tests the weight-loss medicine survodutide against a placebo
- 2Involves weekly injections and lifestyle counseling for about 19 months
- 3Open to adults with overweight or obesity and type 2 diabetes
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.